227 related articles for article (PubMed ID: 36112324)
1. Pediatric Drug Safety Surveillance: A 10-Year Analysis of Adverse Drug Reaction Reporting Data in Calabria, Southern Italy.
Leporini C; De Sarro C; Palleria C; Caccavo I; Piro B; Citraro R; De Sarro G
Drug Saf; 2022 Nov; 45(11):1381-1402. PubMed ID: 36112324
[TBL] [Abstract][Full Text] [Related]
2. Rates of spontaneous reports of adverse drug reactions for drugs reported in children: a cross-sectional study with data from the Swedish adverse drug reaction database and the Swedish Prescribed Drug Register.
Wallerstedt SM; Brunlöf G; Sundström A
Drug Saf; 2011 Aug; 34(8):669-82. PubMed ID: 21751827
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Pediatric Reports in the US Food and Drug Administration Adverse Event Reporting System from 2010-2020: A Cross-Sectional Study.
Phan M; Cheng C; Dang V; Wu E; Muñoz MA
Ther Innov Regul Sci; 2023 Sep; 57(5):1062-1073. PubMed ID: 37351842
[TBL] [Abstract][Full Text] [Related]
4. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
Ogar CK; Abiola A; Yuah D; Ibrahim A; Oreagba IA; Amadi EC; Adeyeye MC; Oshikoya KA
Pharmaceut Med; 2019 Apr; 33(2):145-157. PubMed ID: 31933250
[TBL] [Abstract][Full Text] [Related]
5. Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase.
Star K; Norén GN; Nordin K; Edwards IR
Drug Saf; 2011 May; 34(5):415-28. PubMed ID: 21513364
[TBL] [Abstract][Full Text] [Related]
6. Adverse reactions to contrast media: an analysis of spontaneous reports in the database of the pharmacovigilance programme of India.
Kalaiselvan V; Sharma S; Singh GN
Drug Saf; 2014 Sep; 37(9):703-10. PubMed ID: 25085041
[TBL] [Abstract][Full Text] [Related]
7. Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project.
de Bie S; Ferrajolo C; Straus SM; Verhamme KM; Bonhoeffer J; Wong IC; Sturkenboom MC;
PLoS One; 2015; 10(6):e0130399. PubMed ID: 26090678
[TBL] [Abstract][Full Text] [Related]
8. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.
Conte C; Rousseau V; Vert C; Montastruc F; Montastruc JL; Durrieu G; Olivier P
Fundam Clin Pharmacol; 2020 Aug; 34(4):518-520. PubMed ID: 32022302
[TBL] [Abstract][Full Text] [Related]
9. Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years.
Karrer JE; Giovannoni L; Kullak-Ublick GA; Weiler S
Swiss Med Wkly; 2019 Jun; 149():w20085. PubMed ID: 31256417
[TBL] [Abstract][Full Text] [Related]
10. An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme.
Masuka JT; Khoza S
Pharmacol Res Perspect; 2020 Oct; 8(5):e00657. PubMed ID: 32930524
[TBL] [Abstract][Full Text] [Related]
11. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
[TBL] [Abstract][Full Text] [Related]
12. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.
Scavone C; Sessa M; Clementi E; Corrao G; Leone R; Mugelli A; Rossi F; Spina E; Capuano A
BioDrugs; 2018 Dec; 32(6):607-617. PubMed ID: 30341487
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
[TBL] [Abstract][Full Text] [Related]
14. Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden.
Holm L; Ekman E; Jorsäter Blomgren K
Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):335-343. PubMed ID: 28071845
[TBL] [Abstract][Full Text] [Related]
15. Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase® from 1997 to 2017.
Masuka JT; Khoza S
BMC Public Health; 2019 Aug; 19(1):1166. PubMed ID: 31455314
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous reports of vaccination errors in the European regulatory database EudraVigilance: A descriptive study.
Hoeve CE; van Haren A; Sturkenboom MCJM; Straus SMJM
Vaccine; 2018 Dec; 36(52):7956-7964. PubMed ID: 30416019
[TBL] [Abstract][Full Text] [Related]
17. Development of a multivariate prediction model to identify individual case safety reports which require clinical review.
Gosselt HR; Bazelmans EA; Lieber T; van Hunsel FPAM; Härmark L
Pharmacoepidemiol Drug Saf; 2022 Dec; 31(12):1300-1307. PubMed ID: 36251280
[TBL] [Abstract][Full Text] [Related]
18. The Social Impact of Suspected Adverse Drug Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database.
Castillon G; Salvo F; Moride Y
Drug Saf; 2019 Jan; 42(1):27-34. PubMed ID: 30121742
[TBL] [Abstract][Full Text] [Related]
19. Suspected adverse reactions reported for blood, blood components, and blood products in VigiBase.
Samukange WT; Lu TA; Souverein PC; Gardarsdottir H; Mantel-Teeuwisse AK
Transfusion; 2023 May; 63(5):982-992. PubMed ID: 36994873
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous Adverse Drug Reaction Monitoring in a Tertiary Care Centre.
Kaur K; Kanwal P; Goyal P; Singh P; Yakhmi S; Jain S; Kaushal S
Curr Drug Saf; 2020; 15(3):215-221. PubMed ID: 32735525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
